These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
839 related articles for article (PubMed ID: 18945411)
1. Mathematical models of cervical cancer prevention in the Asia Pacific region. Goldie SJ; Diaz M; Kim SY; Levin CE; Van Minh H; Kim JJ Vaccine; 2008 Aug; 26 Suppl 12():M17-29. PubMed ID: 18945411 [TBL] [Abstract][Full Text] [Related]
2. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Goldie SJ; O'Shea M; Campos NG; Diaz M; Sweet S; Kim SY Vaccine; 2008 Jul; 26(32):4080-93. PubMed ID: 18550229 [TBL] [Abstract][Full Text] [Related]
3. Mathematical models of cervical cancer prevention in Latin America and the Caribbean. Goldie SJ; Diaz M; Constenla D; Alvis N; Andrus JK; Kim SY Vaccine; 2008 Aug; 26 Suppl 11():L59-72. PubMed ID: 18945403 [TBL] [Abstract][Full Text] [Related]
4. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa. Kim JJ; Campos NG; O'Shea M; Diaz M; Mutyaba I Vaccine; 2013 Dec; 31 Suppl 5():F60-72. PubMed ID: 24331749 [TBL] [Abstract][Full Text] [Related]
5. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA). Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822 [TBL] [Abstract][Full Text] [Related]
6. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications. Goldie SJ; O'Shea M; Diaz M; Kim SY Reprod Health Matters; 2008 Nov; 16(32):86-96. PubMed ID: 19027626 [TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Goldie SJ; Kim JJ; Kobus K; Goldhaber-Fiebert JD; Salomon J; O'shea MK; Xavier Bosch F; de Sanjosé S; Franco EL Vaccine; 2007 Aug; 25(33):6257-70. PubMed ID: 17606315 [TBL] [Abstract][Full Text] [Related]
8. Recommendations for cervical cancer prevention in Asia Pacific. Garland SM; Cuzick J; Domingo EJ; Goldie SJ; Kim YT; Konno R; Parkin DM; Qiao YL; Sankaranarayanan R; Stern PL; Tay SK; Bosch FX Vaccine; 2008 Aug; 26 Suppl 12():M89-98. PubMed ID: 18945418 [TBL] [Abstract][Full Text] [Related]
9. Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy. Kim JJ; Kobus KE; Diaz M; O'Shea M; Van Minh H; Goldie SJ Vaccine; 2008 Jul; 26(32):4015-24. PubMed ID: 18602731 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. de Kok IM; van Ballegooijen M; Habbema JD J Natl Cancer Inst; 2009 Aug; 101(15):1083-92. PubMed ID: 19571256 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of the introduction of the human papillomavirus vaccine in Honduras. Aguilar IB; Mendoza LO; García O; Díaz I; Figueroa J; Duarte RM; Perdomo G; Garcia AG; Janusz CB Vaccine; 2015 May; 33 Suppl 1():A167-73. PubMed ID: 25919157 [TBL] [Abstract][Full Text] [Related]
12. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium. Demarteau N; Van Kriekinge G; Simon P Vaccine; 2013 Aug; 31(37):3962-71. PubMed ID: 23777952 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia. Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299 [TBL] [Abstract][Full Text] [Related]
14. Prevention of cervical cancer in rural China: evaluation of HPV vaccination and primary HPV screening strategies. Canfell K; Shi JF; Lew JB; Walker R; Zhao FH; Simonella L; Chen JF; Legood R; Smith MA; Nickson C; Qiao YL Vaccine; 2011 Mar; 29(13):2487-94. PubMed ID: 21211586 [TBL] [Abstract][Full Text] [Related]
15. The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands. Bogaards JA; Coupé VM; Meijer CJ; Berkhof J Vaccine; 2011 Nov; 29(48):8929-36. PubMed ID: 21945961 [TBL] [Abstract][Full Text] [Related]
16. Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost-effectiveness analysis. Yamamoto N; Mori R; Jacklin P; Osuga Y; Kawana K; Shibuya K; Taketani Y BJOG; 2012 Jan; 119(2):177-86. PubMed ID: 21794070 [TBL] [Abstract][Full Text] [Related]
17. [Impact of vaccination against oncogenic human papillomavirus on the incidence and mortality of cervical cancer in Germany]. Schneider A; Schwarz TF; Hammerschmidt T; Siebert U Med Klin (Munich); 2007 Jul; 102(7):515-23. PubMed ID: 17634869 [TBL] [Abstract][Full Text] [Related]
18. Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain. Gauthier A; Martín-Escudero V; Moore L; Ferko N; de Sanjosé S; Pérez-Escolano I; Catalá-López F; Ferrer E; Bosch FX Eur J Public Health; 2008 Dec; 18(6):674-80. PubMed ID: 18641420 [TBL] [Abstract][Full Text] [Related]
19. Health and economic impact associated with a quadrivalent HPV vaccine in Italy. Mennini FS; Giorgi Rossi P; Palazzo F; Largeron N Gynecol Oncol; 2009 Feb; 112(2):370-6. PubMed ID: 19041125 [TBL] [Abstract][Full Text] [Related]
20. Epidemiology and prevention of cervical cancer in Indonesia, Malaysia, the Philippines, Thailand and Vietnam. Domingo EJ; Noviani R; Noor MR; Ngelangel CA; Limpaphayom KK; Thuan TV; Louie KS; Quinn MA Vaccine; 2008 Aug; 26 Suppl 12():M71-9. PubMed ID: 18945416 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]